Thomas Hanke

Thomas Hanke

SGC Frankfurt

Hanke

Thomas Hanke

+49 (0)69 798-29313

Affiliations

Biography

Thomas Hanke studied Pharmacy at the Goethe University in Frankfurt. In 2014, he completed his PhD in the field of pharmaceutical chemistry, investigating the synthesis and pharmacological characterization of dual 5-lipoxygenase and microsomal prostaglandin E2 synthase-1 inhibitors as a new alternative strategy for anti-inflammatory drugs. In 2015, he joined Stefan Knapp´s group where he is working on the development of chemical probes for targeting kinases. For that, he is pursuing different strategies, including the synthesis of allosteric kinase inhibitors (e.g. for LIMK1/2) and the synthesis of macrocyclic compounds to generate new chemistry for targeting kinases.

2025

Crystallographic fragment screening reveals ligand hotspots in TRIM21 PRY-SPRY domain.

Kim Y, Lučić A, Lenz C, Farges F, Schwalm MP, Saxena K, Hanke T, Marples PG, Aschenbrenner JC, Fearon D, von Delft F, Krämer A, Knapp S

Commun Chem. 2025-6-14 . 8(1):185 .doi: 10.1038/s42004-025-01574-3

PMID: 40514378

Type II kinase inhibitors that target Parkinson's disease-associated LRRK2.

Raig ND, Surridge KJ, Sanz-Murillo M, Dederer V, Krämer A, Schwalm MP, Lattal NM, Elson L, Chatterjee D, Mathea S, Hanke T, Leschziner AE, Reck-Peterson SL, Knapp S

Sci Adv. 2025-6-4 . 11(23):eadt2050 .doi: 10.1126/sciadv.adt2050

PMID: 40465731

Repurposing of the RIPK1-Selective Benzo[1,4]oxazepin-4-one Scaffold for the Development of a Type III LIMK1/2 Inhibitor.

Mandel S, Hanke T, Mathea S, Chatterjee D, Saraswati H, Berger BT, Schwalm MP, Yamamoto S, Tawada M, Takagi T, Ahmed M, Röhm S, Corrionero A, Alfonso P, Baena M, Elson L, Menge A, Krämer A, Pereira R, Müller S, Krause DS, Knapp S

ACS Chem Biol. 2025-4-14 . .doi: 10.1021/acschembio.5c00097

PMID: 40227881

2024

Critical assessment of LC3/GABARAP ligands used for degrader development and ligandability of LC3/GABARAP binding pockets.

Schwalm MP, Dopfer J, Kumar A, Greco FA, Bauer N, Löhr F, Heering J, Cano-Franco S, Lechner S, Hanke T, Jaser I, Morasch V, Lenz C, Fearon D, Marples PG, Tomlinson CWE, Brunello L, Saxena K, Adams NBP, von Delft F, Müller S, Stolz A, Proschak E, Kuster B, Knapp S, Rogov VV

Nat Commun. 2024-11-26 . 15(1):10204 .doi: 10.1038/s41467-024-54409-5

PMID: 39587067

Back-Pocket Optimization of 2-Aminopyrimidine-Based Macrocycles Leads to Potent EPHA2/GAK Kinase Inhibitors.

Gerninghaus J, Zhubi R, Krämer A, Karim M, Tran DHN, Joerger AC, Schreiber C, Berger LM, Berger BT, Ehret TAL, Elson L, Lenz C, Saxena K, Müller S, Einav S, Knapp S, Hanke T

J Med Chem. 2024-7-19 . .doi: 10.1021/acs.jmedchem.4c00411

PMID: 39028937

Synthesis and evaluation of chemical linchpins for highly selective CK2α targeting.

Greco FA, Krämer A, Wahl L, Elson L, Ehret TAL, Gerninghaus J, Möckel J, Müller S, Hanke T, Knapp S

Eur J Med Chem. 2024-7-14 . 276:116672 .doi: 10.1016/j.ejmech.2024.116672

PMID: 39067440

Development of Selective Pyrido[2,3-d]pyrimidin-7(8H)-one-Based Mammalian STE20-Like (MST3/4) Kinase Inhibitors.

Rak M, Menge A, Tesch R, Berger LM, Balourdas DI, Shevchenko E, Krämer A, Elson L, Berger BT, Abdi I, Wahl LM, Poso A, Kaiser A, Hanke T, Kronenberger T, Joerger AC, Müller S, Knapp S

J Med Chem. 2024-2-29 . .doi: 10.1021/acs.jmedchem.3c02217

PMID: 38422480

Back-pocket optimization of 2-aminopyrimidine-based macrocycles leads to potent dual EPHA2/GAK kinase inhibitors with antiviral activity.

Gerninghaus J, Zhubi R, Kraemer A, Karim M, Tran DHN, Joerger AC, Schreiber C, Berger LM, Berger BT, Ehret TAL, Elson L, Lenz C, Saxena K, Mueller S, Einav S, Knapp S, Hanke T

bioRxiv. 2024-2-18 . .doi: 10.1101/2024.02.18.580805

PMID: 38405908

2023

Synthesis of Pyrazole-Based Macrocycles Leads to a Highly Selective Inhibitor for MST3.

Amrhein JA, Berger LM, Balourdas DI, Joerger AC, Menge A, Krämer A, Frischkorn JM, Berger BT, Elson L, Kaiser A, Schubert-Zsilavecz M, Müller S, Knapp S, Hanke T

J Med Chem. 2023-12-21 . .doi: 10.1021/acs.jmedchem.3c01980

PMID: 38126712

Design and Synthesis of Pyrazole-Based Macrocyclic Kinase Inhibitors Targeting BMPR2.

Amrhein JA, Wang G, Berger BT, Berger LM, Kalampaliki AD, Krämer A, Knapp S, Hanke T

ACS Med Chem Lett. 2023-6-8 . 14(6):833-840 .doi: 10.1021/acsmedchemlett.3c00127

PMID: 37312836